Evgen Pharma Share Discussion Threads

[moneymunch] 20/9/2021 07:08

RNS Number : 1988M Evgen Pharma PLC 20 September 2021 Evgen Pharma plc ("Evgen" or the "Company") Publication shows effectiveness of SFX-01 in patient derived glioblastoma cells University of Auckland data Evgen Pharma plc (AIM: EVG), a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, notes the publication of data in glioblastoma cells (GBM) generated by Dr Euphemia Leung and Prof Bruce Baguley of the University of Auckland, New Zealand in the pre-print journal BioRxIV (Leung, Wright and Baguley, 2021 https://www.biorxiv.org/content/10.1101/2021.09.14.459936v1). The in vitro data show effectiveness of the Company's lead asset SFX-01 in glioblastoma cells and 3D spheroids from several patients in New Zealand, together with the more commonly used commercially available cell lines. 3D spheroids are aggregations of tumour cells that more closely reflect the structure of tumours in patients. In these in vitro experiments, SFX-01 demonstrated inhibition of glioblastoma cell growth, confirming work previously announced by the Company in another academic centre. Evgen recently announced the grant of Orphan Drug Designation in the USA for Malignant Glioma, affording the programme additional data protection and other incentives. Dr Huw Jones, CEO of Evgen, commented: "This careful and well-controlled set of experiments by Dr Leung and Prof Baguley confirm work communicated to us by Dr Festuccia of the University of L'Aquila, Abruzzo, Italy and are now available through the rapid publication BioRxIV. We noted the effects observed by the Auckland group in a previous communication and the data are now available for inspection via the journal. They serve to confirm the potential efficacy of SFX-01 in cells that are arguably more disease relevant than those more commonly used.''

[jamjamjam1] 17/9/2021 21:44

Ameretto, moneymerch and that cantankerous knowledge box who commenced the other evgen mason esque board. It's our time. It really is.

[trad3m3] 17/9/2021 10:22

Ged5 Dr Paul has a valid point, it is time we begin using new drugs as those we have currently have failed spectacularly. With estimated cancer rates now in every 1 in 2 people will het it, undoubtably we are in a dire need for new solutions and drugs. If Evgen is the solution 70 would be just a day or two stop to reload the indicators, but if the drug approved and successful, would it be available to all, or would it be boiling down to let me see if I can afford to live longer?

[ged5] 17/9/2021 09:01

Interview on BBC1 this morning with Tom Parker talking about his brain tumour. He wants to raise money to tackle this disease. He feels the companies are onthe cusp of finding a cure. Monday at the Royal Albert Hall he has organised a concert to raise money for charities to research brain tumours. There was a follow up interview with Dr Paul Mulholland consultant medical oncologist at UCL hospitals who was raising awareness about Glioblastoma. He asks the question why not use new treatments first, the old ones don't really work.

[trad3m3] 16/9/2021 16:25

Alright then. It will hit 70!

[small crow] 16/9/2021 14:50

Its "..methinks..." verily sire.

[on target] 16/9/2021 14:49

The one from 25/8 has been filled today.

[trad3m3] 16/9/2021 14:27

Me think that the gap must be filled :)

[on target] 16/9/2021 14:13

70p (or more) maybe on a successful result but might be a little bit ambitious on FDA approval? Can see upto 30p perhaps - all depends on the mood of the market though!

[abbynat] 16/9/2021 14:04

if, if, if,if only!

[trad3m3] 16/9/2021 14:00

Daily lovely positioned for the first fib shoot :) if this is the bottom then we shall see 11 in the coming weeks and if FDA approved then transformational 70 first stop :)

[trad3m3] 16/9/2021 13:21

Uuu zee dippa gobble time :)

[lovewinshatelosses] 07/9/2021 20:48

If Bo Zo is a Libertarian Tory, I am a passionate advocate of CRT. Just to be clear, I most certainly am not. As long as we are stuck with chocolate teapot opposition, I guess we are equally stuck with these cretins who merrily discard cast iron manifesto promises. Next up: we are not a 'papers please' society, where vaccine passports are not going to happen...to 'oh, actually, yes they will, but we never said otherwise; you must have misunderstood. Next time, check the small print'. Gas lighting on the public purse style. I just hope he is our Caligula, with someone better to follow...although then we may next get a Nero, so it would only be a temporary respite! Anyway, moving away from the last (decent) days of Rome theme, hopefully we will get some positive partner news here before too long, which would at least provide a welcome distraction from the smell of economic burning and the increased risk of stagflation from regressive tax policy...

[small crow] 07/9/2021 19:58

We have a shagger-jester, rather than a warrior-monk, for a PM. What did we expect?

[bocker01] 07/9/2021 19:14

Seems Boris is not aware that liars become less convincing when they break their promises. Trust, hard to gain, easily lost.

[moneymunch] 06/9/2021 12:01

Bristol Myers Squibb catches the SHP2 wave in a new collaboration deal with BridgeBio Once considered “undruggable,” the phosphatase enzyme SHP2 has seen recent interest from a suite of Big Pharmas, including AstraZeneca, Amgen, Novartis and Merck. Now Bristol Myers Squibb is getting in on the action, with a deal to pair its PD-1 superstar Opdivo with BridgeBio’s SHP2 inhibitor for difficult-to-treat cancers. BMS and BridgeBio took the wraps off the non-exclusive, co-funded collaboration early Tuesday morning. The “catalyst,R21; BridgeBio CBO Michael Henderson said, was last year’s virtual JP Morgan conference, where the companies met to discuss early preclinical results they were seeing between SHP2 and immuno-oncology therapies. SHP2 is a phosphatase that links growth factor, cytokine and integrin signaling with the downstream RAS/ERK MAPK pathway to regulate cellular proliferation and survival. What does that mean? Overexpression of SHP2, for instance, has a downstream signaling effect on tumor cell growth. It’s been suggested that SHP2 has an effect on the tumor microenvironment, and sensitivity to immuno-oncology therap     13 July 2021 Evgen Pharma plc ("Evgen" or "the Company") Early data for SFX-01 in leukaemia cell lines Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, announces preclinical data demonstrating that SFX-01 was effective in in vitro models of certain blood cancers. The data were generated by Dr Eleni Louka and Professor Adam Mead of the MRC Weatherall Institute of Molecular Medicine at Oxford University. The study investigated the effect of SFX-01 on cells from tissue donated by patients with Juvenile Myelomonocytic Leukaemia ("JMML"), through the UK Paediatric MDS/JMML study. These patients carry a specific mutation of the PTPN11 gene. The data demonstrated significant reduction of cell proliferation and increased apoptosis (cell death) of JMML stem cells in the presence of SFX-01, compared to normal controls. The study also showed that SFX-01 significantly impacted cell proliferation and increased cytotoxicity in GDM-1 cells, an Acute Myelomonocytic Leukaemia cell line ("AML"). Whilst this is preliminary data from a small sample size, the Company was encouraged to observe a statistically significant effect in reducing cell proliferation and increasing apoptosis. The PTPN11 gene codes for the SHP2 protein (Src homology-2 domain-containing protein tyrosine phosphatase-2). In January, Evgen announced in-vitro and in-vivo data generated by Professor Philip Eaton, Queen Mary University of London, demonstrating that SFX-01 modifies SHP2. Mutations of the PTPN11 gene are among the commonest molecular defects described in JMML patients, indicating that SFX-01 should be investigated further as a potential disease modifying agent in PTPN11-mutated haematological malignancies. The Company is now assessing the optimal preclinical and clinical strategy for a development programme of SFX-01 in blood cancers such as JMML and AML and will update shareholders when this is completed. Dr Huw Jones, CEO of Evgen Pharma, commented: "The data from Oxford and Queen Mary's shows a very exciting opportunity to extend our oncology pipeline by adding blood cancers to the ongoing metastatic breast cancer and glioblastoma programmes. We are grateful to Professor Eaton, Professor Mead and Dr Louka for their thoughtful and well conducted work on these important cancers."

[on target] 06/9/2021 10:55

Shake-out of small fish to get stock for the bigger fish.

[herb clark] 06/9/2021 10:13

Cannot believe the drop here!

[moneymunch] 03/9/2021 19:09

13/7/21 Dr Huw Jones, CEO of Evgen, commented: "Given the progress with our glioma programme and our intent to commence trials in 2022, we are seeking Orphan Drug status to maximise our intellectual property protection, commercial potential and partner appeal in this devastating disease. The incentives offered by OD designation mean that rare diseases like glioblastoma are more likely to be researched in the clinic. "

[moneymunch] 03/9/2021 16:09

Can't help thinking there could be a significant reason for the speed the FDA granted Orphan Drug designation, especially during the holiday season when you'd expect things to go slow......here's hoping a commercial partner in the pipeline ( with influence ) is the reason. Gla ;-)

[amaretto1] 03/9/2021 15:59

And another thing ... :-)

[jusjusjus] 03/9/2021 15:57

"Anyway I’m not saying another word on matter."